GenKyoTex SA (GKTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GenKyoTex SA (GKTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH137088D
  • |
  • Pages: 38
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

GenKyoTex SA (GenKyoTex), formerly Genticel SA is a drug development company that develops NOX therapies. The company develops targeted NOX inhibitors. It develops molecule therapeutics that inhibits the NOX family of enzymes. GenKyoTex's product includes GKT137831, a selective NOX1/4 inhibitor in phase II clinical development for the treatment. The company's products are used in the treatment of diabetic nephropathy. It also used in treating several other disease models such as atherosclerosis, osteoporosis, lung and liver fibrosis, and models of angiogenesis. The company has its operations in Switzerland and France. GenKyoTex is headquartered in Saint-Julien- en-Genevois, France.

GenKyoTex SA (GKTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

GenKyoTex SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

GenKyoTex SA, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

GenKyoTex Raises USD21 Million in Series D Financing 10

GenKyoTex Raises USD 26 Million In Extended Series C Financing 12

Merger 14

Genticel Merges with GenKyoTex 14

Licensing Agreements 16

Serum Institute Expands Licensing Agreement with Genkyotex 16

Equity Offering 17

GenKyoTex Plans to Raise Funds through IPO 17

Debt Offering 18

Genkyotex to Raise USD5.7 Million in Private Placement of 15% First Tranche Notes Due 2019 18

GenKyoTex SA-Key Competitors 20

GenKyoTex SA-Key Employees 21

GenKyoTex SA-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Feb 28, 2018: Genkyotex Reports 2017 Financial Results 23

Oct 26, 2017: Genkyotex Provides Business Update for Q3 2017 25

Sep 21, 2017: Genkyotex Announces 2017 First-Half Financial Results 26

Apr 27, 2017: Genkyotex Provides Business Update for Q1 2017 28

Product News 29

10/26/2017: Genkyotex Provides Business Update For Q3 2017 29

Clinical Trials 30

May 07, 2018: Genkyotex Announces Positive Outcome from Independent SMB's First Pre-Planned Review of GKT831's Phase 2 Trial in Primary Biliary Cholangitis 30

Aug 03, 2017: Genkyotex's GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated Fibroblasts 31

Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis 32

May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis 33

Other Significant Developments 34

Apr 25, 2018: Genkyotex Reports March 31, 2018 Cash Position and Provides Business Update 34

Jan 31, 2018: Genkyotex Reports December 31, 2017 Cash Position and Provides Business Update 35

Jul 27, 2017: Genkyotex Provides Business Update for Q2 2017 36

Jun 05, 2017: Edison Issues Outlook on Genkyotex 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38

List of Figures

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

GenKyoTex SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

GenKyoTex SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

GenKyoTex SA, Deals By Therapy Area, 2012 to YTD 2018 8

GenKyoTex SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

GenKyoTex Raises USD21 Million in Series D Financing 10

GenKyoTex Raises USD 26 Million In Extended Series C Financing 12

Genticel Merges with GenKyoTex 14

Serum Institute Expands Licensing Agreement with Genkyotex 16

GenKyoTex Plans to Raise Funds through IPO 17

Genkyotex to Raise USD5.7 Million in Private Placement of 15% First Tranche Notes Due 2019 18

GenKyoTex SA, Key Competitors 20

GenKyoTex SA, Key Employees 21

GenKyoTex SA, Subsidiaries 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

GenKyoTex SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18043
Site License
USD 500 INR 36085
Corporate User License
USD 750 INR 54128

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com